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Abstract
Background. Control of intraoperative hemorrhage represents a significant challenge in hepatic surgery, particularly during
resection of large, hypervascular hepatic hemangiomata (HH). Various devices to minimize blood loss from hepatic
parenchymal transection are currently under investigation. Herein, we present our experience with a radiofrequency (RF)-
powered multiarray for resection of HH. Patients and methods. From September 2005 to January 2006, we conducted a
retrospective review of our hepatobiliary database to identify patients with symptomatic giant cavernous HH undergoing
resection with a RF multiarray device. The purpose of this review was to assess the technical aspects of using RF energy to
assist in the resection of HH. Results. The extent of operation varied depending on the size and location of the tumor. Two
patients underwent two atypical subsectionectomies and two underwent trisectionectomies. The HabibTM sealer provided a
safe and effective method for hepatic parenchymal transaction. No patients required blood transfusion, and no injuries to
major biliary or vascular strictures were observed at 1 year follow-up. A seroma developed in one patient 6 months
postoperatively, but was drained percutaneously. Conclusions.Hepatic parenchymal transection with the Habib sealer device
is a feasible approach to resect HH. Further study is needed to objectively compare the efficacy of RF-assisted parenchymal
transection with that of traditional parenchymal transection techniques.
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Introduction
Hepatic surgery has undergone a dramatic evolution
in the past quarter century. Once burdened with
prohibitively high morbidity and mortality, hepatic
resection is now considered a safe standard of care in
appropriately selected patients with hepatic tumors.
Advances in surgical technique, anesthesia, and cri-
tical care have reduced operative mortality to B5% in
most major academic centers [1]. While several less
invasive liver-directed therapies have emerged, hepatic
resection is the only potentially curative treatment
option in patients with malignant or symptomatic
benign hepatic tumors. Nevertheless, liver surgery
remains a potentially high-risk procedure requiring a
great deal of operative experience and technical
expertise.
Of chief concern among hepatic surgeons is the
potential for intraoperative blood loss associated with
liver resection. According to a recent review, the
average estimated blood loss from hepatic resection
in high volume centers approached as much as 500 ml
[2]. Several strategies  including low CVP anesthe-
sia, the Pringle maneuver, and total hepatic vascular
exclusion  are presently employed to minimize
hemorrhage during hepatic resection. In addition,
specialized hepatic parenchymal transection devices
such as the ultrasonic aspirator, jet dissector, ultra-
sonic shears, bipolar vessel sealer, linear endocutter,
and saline-enhanced radiofrequency (RF) dissecting
sealer have been developed to promote hemostasis
during resection.
Recently, another device called the HabibTM sealer
was introduced as a potentially useful tool to mini-
mize blood loss during hepatic resection. This RF
sealer employs RF energy to facilitate relatively
‘bloodless’ parenchymal dissection. Habib et al. first
described its use in 2001 [3]; they showed that
by creating a 23 cm wide zone of coagulative
necrosis, RF energy provided a charred, avascular
bed that could be sharply divided with minimal blood
loss during parenchymal dissection. While previous
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studies demonstrate the utility of the HabibTM sealer
for resection of malignant hepatic tumors, no reports
exist on the potential role of the device in resection of
benign vascular liver lesions. Herein, we present four
patients with symptomatic hepatic hemangioma (HH)
who underwent RF-assisted parenchymal transection
with an RF-powered parenchymal transection device.
Surgical technique
Initial exposure and mobilization of the liver were
performed in standard fashion. Briefly, the abdomen
was entered using a right subcostal ‘hockey stick’
incision. The falciform ligament was divided and
ligated. A self-retaining retractor was placed to retract
the costal margin to provide optimal exposure. The
ligamentous attachments to the right and left liver
lobes were divided as needed, and the triangular
ligament was released, exposing the ipsilateral hepatic
veins.
The gastrohepatic ligament was then incised and
the portal region explored. All visible arteries supply-
ing the lobe that contained the hemangioma were
ligated with suture, resulting in dermacation and
reduction in the size of the hemangioma. A vessel
loop was placed around the porta hepatic to facilitate
a Pringle maneuver. Further mobilization of the liver
was performed posteriorly off the retroperitoneum to
expose the vena cava. After exposure, mobilization,
and vascular control of the liver were complete, a
cholecystectomy was performed in top-down fashion.
While the preceding operative steps were un-
changed from our standard approach to hepatectomy,
the next stage in the operation  parenchymal
transection  differed substantially. After mapping
the course of hepatic veins and margins of the
hemangioma with intraoperative ultrasound, we used
the HabibTM RF device to create a coagulative plane
just outside the hemangioma. The RF generator was
set to an energy setting of 70 W and the electrode was
applied to the hepatic parenchyma, delivering current
to the tissue to induce coagulation necrosis. Once the
plane of coagulation was created, the parenchyma was
cut with a straight scalpel. During the course of
transection, careful attention was paid to the hepatic
vasculature and biliary ducts encountered in the field
of resection. All hepatic veins 3 mm and suspected
biliary structures at the plane of transection were
suture ligated. Minor bleeding from the cut surface of
the parenchyma was coagulated with an argon beam.
The transection plane was then closely inspected for
biliary leaks. A clean white laparotomy sponge was
applied to the cut surface. The cystic duct was
cannulated with a catheter and the distal porta hepatic
occluded while methylene blue dye was injected to
assess for the presence of bile leak. After hemostasis
was assured, the abdomen was closed in standard
fashion.
Results
Four patients with symptomatic (pain, gastric com-
pression) giant cavernous HH underwent RF
parenchymal transection using the HabibTM sealer
device. The extent of resection varied among the
patients, with two patients undergoing atypical sub-
sectionectomies, one undergoing lobectomy, and one
trisectionectomy. Standard mobilization of the liver
and control of inflow and outflow vessels were
required for the treatment of these large hemangio-
mas. (See Figures 13 and Table I.)
Several technical principles were rigorously adhered
to during parenchymal transection with the RF
device. Before entering parenchyma feeding arteries
were ligated. First, all hepatic veins 3 mm in
diameter in the plane of transection were suture
ligated. This minimized the ‘heat sink’ effect of blood
flow, resulting in optimal delivery of energy to the
tissue. Second, all biliary structures 2 mm in dia-
meter were suture ligated. Strict adherence to this
criterion resulted in no observed biliary leaks either
intraoperatively or postoperatively. In addition, we
performed the majority of our ablations at a power
setting of 70 W. Early on in our experience, we used
Figure 1. Giant cavernous hepatic hemangioma in right hepatic
lobe.
Figure 2. Parenchymal transection using the HabibTM needle.
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power settings in excess of 100 W. This level of energy
was associated with ‘superheating’ and sudden explo-
sions of the liver tissue, which could potentially cause
cracking and massive hemorrhage from the parench-
yma if a hepatic or portal vein was in close proximity.
Therefore, all subsequent ablations were performed at
a power setting of 70 W. This energy level resulted in
an effective and safe ablation of hepatic parenchyma.
Hepatic veins 3 mm in diameter were not sealed
with this device in the coagulated plane of transection,
necessitating suture ligation. The coagulative necrosis
of the parenchyma resulted in very firm, noncom-
pressible liver tissue, which held sutures very well.
However, the firmness of the coagulated tissue plane
prevents easy and safe passage of a linear endocutter
or clamp, thus making division of larger hepatic veins
potentially problematic and dangerous. For this
reason, it is essential that the surgeon knows the exact
course and location of major hepatic veins that require
transection by using intraoperative ultrasound before
applying the RF current. We purposely created a
shallower plane of precoagulation that was superficial
to the major hepatic veins as they converged with the
vena cava in the most cephalad portion of the
parenchymal transection, so that we could more safely
and carefully isolate them for clamping and division.
In summary, the RF device facilitated expedient
hepatic parenchymal transection. The estimated over-
all operative time did not differ from historical
controls. Further, the HabibTM sealer demonstrated
an excellent overall safety profile in these four
patients. The use of a 70 W power setting, coupled
with careful hepatic venous and biliary radical liga-
tion, resulted in safe and effective parenchymal
transection. No injuries to major biliary or vascular
structures were observed. Estimated blood loss was
similar to historical controls, and no incidences of
postoperative bleeding requiring transfusion were
noted; two patients required intraoperative transfu-
sion. In addition, we observed no clinically evident
bile leaks postoperatively. There was one seroma
necessitating percutaneous drainage at 6 months.
Discussion
HHs are the most common benign vascular tumor of
the liver [4]. Originating as abnormalities of the
hepatic sinusoidal vascular endothelium, hemangio-
mas grow by progressive vascular ectasia rather than
infiltration and angiogenesis. Several definitions exist
in the literature for giant hepatic hemangioma.
Adam et al. in 1970 described giant HHs as 4 cm
in diameter [5], although in 1982, in Diseases of
the Liver the definition of 1012 cm was used [6].
Regardless of their size, hemangiomas are typically
asymptomatic, presenting as incidental findings dur-
ing radiologic work-up of an unrelated illness. These
lesions may produce symptoms, the most common
being vague abdominal pain or discomfort. Rarely,
hemangiomas may rupture, leading to potentially
life-threatening intraparenchymal or intraperitoneal
hemorrhage.
Hemangiomas are typically distinguished from
other hepatic lesions on the basis of their radiologic
appearance. Ultrasound, contrast-enhanced CT, and
MRI are the three most common imaging modalities
used to confirm the diagnosis of hemangioma. Ultra-
sound shows either a hyperechoic lesion with no
posterior shadowing or a hypoechoic or isoechoic
lesion with a hyperechoic rim [4]. Contrast-enhanced
CT typically demonstrates three distinct findings,
based on the contrast phase. Precontrast images
show a well-circumscribed hypodense lesion; contrast
infusion results in peripheral nodular enhancement
of the lesion. On delayed images, the tumor centripe-
tally enhances and ultimately appears as an isodense
lesion [4]. When ultrasound or CT fails to elucidate
the diagnosis, MRI is performed. MRI is considered
the best imaging study as it provides for superior
lesion detection and characterization. Hemangiomas
appear as low density lesions on T1-weighted images
and high density lesions on T2-weighted images;
Figure 3. Cut surface of the transected parenchyma shows coagula-
tion necrosis. Hepatic veins are suture ligated.
Table I. Patient characteristics.
Gender Age (years) Tumor size (cm) Location Indication EBL (ml) Transfusion (units)
F 50 151013 Left trisegmentectomy Pain, early satiety 1000 2
F 44 272014 Right trisegmentectomy Nausea, early satiety 1500 2
F 63 10812 Segment 3 Back pain, nausea 50 0
F 67 25 Segments 5 and 6 Pain 750 0
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gadolinium contrast induces peripheral enhancement
of the tumor [7].
While most hemangiomas are asymptomatic and
need only to be observed, hemangiomas that pro-
duce intractable symptoms should be treated. Re-
ported indications for resection include pain, rapid
growth, intraperitoneal bleeding, thrombocytopenia
(i.e. Kasabach-Merritt syndrome) and involvement in
contact sports [8]. Before initiating treatment, all
other possible etiologies for the patient’s symptoms
must be ruled out. Treatment of hemangioma varies
based on the patient’s presentation and underlying
medical condition. At present, no effective medical
therapy exists for hemangioma. The only available
therapies for HH are transcatheter ablation [9],
irradiation [10], or surgical resection. The first two
are generally reserved for patients who are poor
operative candidates. Transcatheter arterial emboliza-
tion may also be used to achieve temporary hemos-
tasis of ruptured hemangiomas.
At present, the only definitive therapy for HH is
surgical resection. Several approaches to resection
are available and should be tailored to the tumor’s
location and characteristics as well as the patient’s
overall health. Wedge resection and anatomical lobec-
tomy were first reported in the late 1800s and
remained the standard surgical approach to heman-
gioma resection. Another surgical option for heman-
gioma is enucleation [11]. HHs often develop a
fibrous pseudocapsule that separates them from
normal liver parenchyma; this pseudocapsule provides
a bloodless plane for dissection, allowing enucleation
of the lesion. Regardless of the operation, most
hemangiomas are approached by an open laparotomy.
Laparoscopy has a limited role in hemangioma resec-
tion, although a few case reports exist in the literature
[12,13].
Due to their large size and generous blood supply,
hemangiomas are particularly susceptible to hemor-
rhage during resection. In particular, tumors larger
than 10 cm were found to be associated with
increased intraoperative blood loss [14]. This is of
particular concern because it has been reported that
intraoperative blood loss requiring blood transfusion
positively correlates with morbidity and mortality
[15]. For this reason, several techniques are employed
to minimize the risk of hemorrhage, including the
Pringle maneuver and ligation of any hepatic arterial
branches that feed the lobe containing the tumor.
Given the generally recognized large blood loss during
hemangioma resection, new parenchymal transection
devices such as the HabibTM sealer may have the
potential to reduce blood loss for hepatic resection
with this indication, given the observations from other
indications for hepatic resection. In the present series,
it was not our observation that the blood loss was
reduced compared to our general previous experience;
however, from this limited initial experience no
comparison on this parameter would be appropriate.
It should be noted that hepatic resections with the
indication of symptomatic hemangioma constitute
between 8% and 10% of our annual hepatic resection
experience.
RF ablation (RFA) involves the use of a high
frequency current delivered to tissues through an
electrode. Alternating current causes the ions in the
vicinity of the electrode to rapidly change direction
(ionic agitation), leading to frictional heating and
coagulative necrosis of tissue. Cell death occurs at
498C after 49 min [16]. Laparoscopic RFA, without
resection, has been used to treat HH. Fan et al.
reported 27 patients treated with laparoscopic RFA
with no recurrence at a mean of 21 months [17]. Still,
the authors recommend that tumors larger than 10
cm be treated open with resection to prevent risk of
massive bleeding. In a series from Penn State and
UCLA on giant cavernous liver hemangiomas, multi-
ple techniques were employed, including lobectomy
with use of ultrasonic sealers and enucleation [18].
Their reported transfusions were a mean of 3.3 U for
enucleation and 4.4 U for lobectomy. No data on
blood loss were given.
Classic liver surgery techniques still apply when
using this RFA device. Knowledge of hepatic vein
orientation is essential. Hepatic veins 3 mm that are
located within the plane of transection require in-
dependent ligation, either because there is inadequate
shrinkage of the parenchyma to compress vessels of
this size or due to the heat sink effect that causes
inadequate energy deposition due to convective heat
transfer by rapid blood flow in these vessels causing
incomplete coagulation. Similarly, biliary structures
2 mm also require suture ligation. We have found
that large biliary channels will leak upon methylene
blue injection if not independently ligated. Although a
heat sink is likely not responsible, knowledge of
anatomy and attention to biliary size is required to
avoid postoperative leak.
Theoretically, the potential large amount of coagu-
lation necrosis along the plane of transection poses a
risk for postoperative infection; however, in the
present experience no hepatic abscess or subhepatic
collections were observed.
Another interesting observation from this experi-
ence was the occurrence of a ‘superheating’ phenom-
enon of the parenchyma with resultant parenchymal
fracture (‘sudden popping’) occurring. This event was
associated with the use of the device at the power
setting of 100 W. This can be alarming given the
sudden cracking and explosion of the tissue that likely
results from the rapid rise of intracellular tempera-
tures to 1008C. Parenchymal ablation is achieved in
about 47 seconds with a setting of 70 W. Therefore
we have subsequently used the device at this setting,
without further events. Interestingly, the senior
author’s personal communication with the company
revealed the present day general recommendation for
power setting to be in the area of 7090 W.
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As would be expected, the RFA-associated phe-
nomenon of ‘outgassing’ was also observed by in-
traoperative ultrasound of the liver parenchyma
undergoing heating. As the parenchyma is heated,
the solubility of dissolved nitrogen is decreased,
resulting in microbubble formation [19]. We did not
observe any correlation between outgassing and the
power setting used.
The HabibTM RF device adds to the armamentar-
ium of transection devices available to the hepatic
surgeon. When used properly and with intraoperative
ultrasound, RFA may be suitable for parenchyma-
sparing hepatectomy, as long as the principles of
standard hepatic resection are employed [20]. Our
early experience with this RF parenchymal ablation
device did not result in bile leak or postoperative
bleeding. While there is a quick learning curve
associated with the technical aspects of this device,
we recommend careful attention to the principles of
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